Reviews
Tingting Yan, Nana Yan, Ping Wang, Yangliu Xia, Haiping Hao, Guangji Wang, Frank J. Gonzalez. Herbal drug discovery for the treatment of nonalcoholic fatty liver disease[J]. Acta Pharmaceutica Sinica B, 2020, 10(1): 3-18

Herbal drug discovery for the treatment of nonalcoholic fatty liver disease
Tingting Yana, Nana Yanb, Ping Wanga,c, Yangliu Xiaa,d, Haiping Haob, Guangji Wangb, Frank J. Gonzaleza
a Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA;
b State Key Laboratory of Natural Medicines, Key Laboratory of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing 210009, China;
c Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China;
d School of Life Science and Medicine, Dalian University of Technology, Panjin 124221, China
Abstract:
Few medications are available for meeting the increasing disease burden of nonalcoholic fatty liver disease (NAFLD) and its progressive stage, nonalcoholic steatohepatitis (NASH). Traditional herbal medicines (THM) have been used for centuries to treat indigenous people with various symptoms but without clarified modern-defined disease types and mechanisms. In modern times, NAFLD was defined as a common chronic disease leading to more studies to understand NAFLD/NASH pathology and progression. THM have garnered increased attention for providing therapeutic candidates for treating NAFLD. In this review, a new model called “multiple organs-multiple hits” is proposed to explain mechanisms of NASH progression. Against this proposed model, the effects and mechanisms of the frequentlystudied THM-yielded single anti-NAFLD drug candidates and multiple herb medicines are reviewed, among which silymarin and berberine are already under U.S. FDA-sanctioned phase 4 clinical studies. Furthermore, experimental designs for anti-NAFLD drug discovery from THM in treating NAFLD are discussed. The opportunities and challenges of reverse pharmacology and reverse pharmacokinetic concepts-guided strategies for THM modernization and its global recognition to treat NAFLD are highlighted. Increasing mechanistic evidence is being generated to support the beneficial role of THM in treating NAFLD and anti-NAFLD drug discovery.
Key words:    Natural products    Fatty liver    Metabolic syndrome    TCM    NAFLD   
Received: 2019-07-24     Revised: 2019-09-23
DOI: 10.1016/j.apsb.2019.11.017
Funds: Diane Cooper, MS, NIH Library, participated in writing the manuscript. This work was supported by the intramural research program of the National Cancer Institute, National Institutes of Health.
Corresponding author: Tingting Yan, Frank J. Gonzalez     Email:Tingting.yan@nih.gov;gonzalef@mail.nih.gov
Author description:
Service
PDF(KB) Free
Print
0
Authors
Tingting Yan
Nana Yan
Ping Wang
Yangliu Xia
Haiping Hao
Guangji Wang
Frank J. Gonzalez

References:
1. Wree A, Broderick L, Canbay A, Hoffman HM, Feldstein AE. From NAFLD to NASH to cirrhosisdnew insights into disease mechanisms. Nat Rev Gastroenterol Hepatol 2013;10:627-36.
2. Michelotti GA, Machado MV, Diehl AM. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol 2013;10:656-65.
3. Zhu JZ, Dai YN, Wang YM, Zhou QY, Yu CH, Li YM. Prevalence of nonalcoholic fatty liver disease and economy. Dig Dis Sci 2015;60: 3194-202.
4. Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. J Hepatol 2017;67:862-73.
5. Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 2018;15: 11-20.
6. Oseini AM, Sanyal AJ. Therapies in non-alcoholic steatohepatitis (NASH). Liver Int 2017;37 Suppl 1:97-103.
7. Cassidy S, Syed BA. Nonalcoholic steatohepatitis (NASH) drugs market. Nat Rev Drug Discov 2016;15:745-6.
8. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, van Natta ML, Abdelmalek MF, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 2015;385:956-65.
9. Ratziu V, Harrison SA, Francque S, Bedossa P, Lehert P, Serfaty L, et al. Elafibranor, an agonist of the peroxisome proliferator-activated receptor-alpha and -delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology 2016;150: 1147-59.
10. Connolly JJ, Ooka K, Lim JK. Future Pharmacotherapy for nonalcoholic steatohepatitis (NASH): review of phase 2 and 3 trials. J Clin Transl Hepatol 2018;6:264-75.
11. Sumida Y, Yoneda M. Current and future pharmacological therapies for NAFLD/NASH. J Gastroenterol 2018;53:362-76.
12. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, TorresGonzalez A, Gra-Oramas B, Gonzalez-Fabian L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 2015;149: 367-78.
13. Lassailly G, Caiazzo R, Buob D, Pigeyre M, Verkindt H, Labreuche J, et al. Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients. Gastroenterology 2015; 149:379-88.
14. Pengpid S, Peltzer K. Utilization of traditional and complementary medicine in Indonesia: results of a national survey in 2014-15. Complement Ther Clin Pract 2018;33:156-63.
15. Peltzer K, Pengpid S. Utilization and practice of traditional/complementary/alternative medicine (T/CAM) in southeast Asian nations (ASEAN) member states. Stud Ethno-Med 2015;9: 209-18.
16. Seeff LB, Curto TM, Szabo G, Everson GT, Bonkovsky HL, Dienstag JL, et al. Herbal product use by persons enrolled in the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. Hepatology 2008;47:605-12.
17. Seeff LB, Bonkovsky HL, Navarro VJ, Wang G. Herbal products and the liver: a review of adverse effects and mechanisms. Gastroenterology 2015;148:517-32.
18. Shi KQ, Fan YC, Liu WY, Li LF, Chen YP, Zheng MH. Traditional Chinese medicines benefit to nonalcoholic fatty liver disease: a systematic review and meta-analysis. Mol Biol Rep 2012;39: 9715-22.
19. Ratziu V, Goodman Z, Sanyal A. Current efforts and trends in the treatment of NASH. J Hepatol 2015;62:S65-75.
20. Pan SY, Litscher G, Gao SH, Zhou SF, Yu ZL, Chen HQ, et al. Historical perspective of traditional indigenous medical practices: the current renaissance and conservation of herbal resources. Evid Based Complement Altern Med 2014;2014:525340.
21. Qiu J. China plans to modernize traditional medicine. Nature 2007; 446:590-1.
22. Cao Y, Pan Q, Cai W, Shen F, Chen GY, Xu LM, et al. Modulation of gut microbiota by berberine improves steatohepatitis in high-fat dietfed BALB/c Mice. Arch Iran Med 2016;19:197-203.
23. Yan HM, Xia MF, Wang Y, Chang XX, Yao XZ, Rao SX, et al. Efficacy of berberine in patients with non-alcoholic fatty liver disease. PLoS One 2015;10. e0134172.
24. Yuan XL, Wang J, Tang XY, Li YX, Xia P, Gao X. Berberine ameliorates nonalcoholic fatty liver disease by a global modulation of hepatic mRNA and lncRNA expression profiles. J Transl Med 2015; 13:24-34.
25. Zhang Z, Li B, Meng X, Yao S, Jin L, Yang J, et al. Berberine prevents progression from hepatic steatosis to steatohepatitis and fibrosis by reducing endoplasmic reticulum stress. Sci Rep 2016;6: 20848.
26. Wah Kheong C, Nik Mustapha NR, Mahadeva S. A randomized trial of silymarin for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2017;15:1940-1949 e8.
27. Wicklow B, Wittmeier K, t’Jong GW, McGavock J, Robert M, Duhamel T, et al. Proposed trial: safety and efficacy of resveratrol for the treatment of non-alcoholic fatty liver disease (NAFLD) and associated insulin resistance in adolescents who are overweight or obese adolescentsd rationale and protocol. Biochem Cell Biol 2015; 93:522-30.
28. Poulsen MK, Nellemann B, Bibby BM, Stodkilde-Jorgensen H, Pedersen SB, Gronbaek H, et al. No effect of resveratrol on VLDLeTG kinetics and insulin sensitivity in obese men with nonalcoholic fatty liver disease. Diabetes Obes Metab 2018;20: 2504-9.
29. Poulsen MK, Nellemann B, Stodkilde-Jorgensen H, Pedersen SB, Gronbaek H, Nielsen S. Impaired insulin suppression of VLDLetriglyceride kinetics in nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2016;101:1637-46.
30. Faghihzadeh F, Adibi P, Rafiei R, Hekmatdoost A. Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease. Nutr Res 2014;34:837-43.
31. Zhang PW, Chen FX, Li D, Ling WH, Guo HH. A CONSORTcompliant, randomized, double-blind, placebo-controlled pilot trial of purified anthocyanin in patients with nonalcoholic fatty liver disease. Medicine (Baltim) 2015;94:e758.
32. Kidd P, Head K. A review of the bioavailability and clinical efficacy of milk thistle phytosome: a silybin-phosphatidylcholine complex (Siliphos). Altern Med Rev 2005;10:193-203.
33. Wong MCS, Huang JLW, George J, Huang J, Leung C, Eslam M, et al. The changing epidemiology of liver diseases in the Asia-Pacific region. Nat Rev Gastroenterol Hepatol 2019;16:57-73.
34. Lazaridis N, Tsochatzis E. Current and future treatment options in non-alcoholic steatohepatitis (NASH). Expert Rev Gastroenterol Hepatol 2017;11:357-69.
35. Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med 2018;24:908-22.
36. Gonzalez FJ, Jiang CT, Xie C, Patterson AD. Intestinal farnesoid X receptor signaling modulates metabolic disease. Dig Dis 2017;35: 178-84.
37. Sharifnia T, Antoun J, Verriere TG, Suarez G, Wattacheril J, Wilson KT, et al. Hepatic TLR4 signaling in obese NAFLD. Am J Physiol Gastrointest Liver Physiol 2015;309:G270-8.
38. Ray K. NAFLD. Leaky guts: intestinal permeability and NASH. Nat Rev Gastroenterol Hepatol 2015;12:123.
39. Leung C, Rivera L, Furness JB, Angus PW. The role of the gut microbiota in NAFLD. Nat Rev Gastroenterol Hepatol 2016;13: 412-25.
40. Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 2016;65: 1038-48.
41. Wan X, Xu C, Yu C, Li Y. Role of NLRP3 inflammasome in the progression of NAFLD to NASH. Chin J Gastroenterol Hepatol 2016;2016:6489012.
42. Kazankov K, Jorgensen SMD, Thomsen KL, Moller HJ, Vilstrup H, George J, et al. The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Nat Rev Gastroenterol Hepatol 2019;16:145-59.
43. Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol 2015;62:S47-64.
44. Xie C, Yagai T, Luo Y, Liang X, Chen T, Wang Q, et al. Activation of intestinal hypoxia-inducible factor 2alpha during obesity contributes to hepatic steatosis. Nat Med 2017;23:1298-308.
45. Jiang C, Xie C, Li F, Zhang L, Nichols RG, Krausz KW, et al. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. J Clin Investig 2015;125:386-402.
46. Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T, et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012;482:179-85.
47. Li G, Xie C, Lu S, Nichols RG, Tian Y, Li L, et al. Intermittent fasting promotes white adipose browning and decreases obesity by shaping the gut microbiota. Cell Metabol 2017;26:672-85.
48. Wree A, Eguchi A, McGeough MD, Pena CA, Johnson CD, Canbay A, et al. NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice. Hepatology 2014;59:898-910.
49. Frasinariu OE, Ceccarelli S, Alisi A, Moraru E, Nobili V. Guteliver axis and fibrosis in nonalcoholic fatty liver disease: an input for novel therapies. Dig Liver Dis 2013;45:543-51.
50. Paolella G, Mandato C, Pierri L, Poeta M, Di Stasi M, Vajro P. Guteliver axis and probiotics: their role in non-alcoholic fatty liver disease. World J Gastroenterol 2014;20:15518-31.
51. Tripathi A, Debelius J, Brenner DA, Karin M, Loomba R, Schnabl B, et al. The guteliver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol 2018;15:397-411.
52. Jiang C, Xie C, Lv Y, Li J, Krausz KW, Shi J, et al. Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. Nat Commun 2015;6:10166.
53. Iacono A, Raso GM, Canani RB, Calignano A, Meli R. Probiotics as an emerging therapeutic strategy to treat NAFLD: focus on molecular and biochemical mechanisms. J Nutr Biochem 2011;22:699-711.
54. Federico A, D’Aiuto E, Borriello F, Barra G, Gravina AG, Romano M, et al. Fat: a matter of disturbance for the immune system. World J Gastroenterol 2010;16:4762-72.
55. Arrese M, Cabrera D, Kalergis AM, Feldstein AE. Innate immunity and inflammation in NAFLD/NASH. Dig Dis Sci 2016;61: 1294-303.
56. Tosello-Trampont AC, Landes SG, Nguyen V, Novobrantseva TI, Hahn YS. Kuppfer cells trigger nonalcoholic steatohepatitis development in diet-induced mouse model through tumor necrosis factoralpha production. J Biol Chem 2012;287:40161-72.
57. Duarte N, Coelho IC, Patarrao RS, Almeida JI, Penha-Goncalves C, Macedo MP. How inflammation impinges on NAFLD: a role for Kupffer cells. BioMed Res Int 2015;2015:1-11.
58. Wree A, McGeough MD, Pena CA, Schlattjan M, Li HY, Inzaugarat ME, et al. NLRP3 inflammasome activation is required for fibrosis development in NAFLD. J Mol Med 2014; 92:1069-82.
59. Mridha AR, Wree A, Robertson AAB, Yeh MM, Johnson CD, van Rooyen DM, et al. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice. J Hepatol 2017;66:1037-46.
60. Pilegaard H, Saltin B, Neufer PD. Exercise induces transient transcriptional activation of the PGC-1alpha gene in human skeletal muscle. J Physiol 2003;546:851-8.
61. Xia B, Cai GH, Yang H, Wang SP, Mitchell GA, Wu JW. Adipose tissue deficiency of hormone-sensitive lipase causes fatty liver in mice. PLoS Genet 2017;13. e1007110.
62. Granneman JG, Burnazi M, Zhu Z, Schwamb LA. White adipose tissue contributes to UCP1-independent thermogenesis. Am J Physiol Endocrinol Metab 2003;285:E1230-6.
63. Kuang J, Zhang Y, Liu Q, Shen J, Pu S, Cheng S, et al. Fat-specific sirt6 ablation sensitizes mice to high-fat diet-induced obesity and insulin resistance by inhibiting lipolysis. Diabetes 2017;66: 1159-71.
64. Taher J, Farr S, Adeli K. Central nervous system regulation of hepatic lipid and lipoprotein metabolism. Curr Opin Lipidol 2017;28:32-8.
65. Morton GJ, Cummings DE, Baskin DG, Barsh GS, Schwartz MW. Central nervous system control of food intake and body weight. Nature 2006;443:289-95.
66. Pimentel GD, Micheletti TO, Pace F, Rosa JC, Santos RVT, Lira FS. Gut-central nervous system axis is a target for nutritional therapies. Nutr J 2012;11:22-30.
67. Gastaldelli A, Marchesini G. Time for glucagon like peptide-1 receptor agonists treatment for patients with NAFLD?. J Hepatol 2016; 64:262-4.
68. Thon M, Hosoi T, Ozawa K. Possible integrative actions of leptin and insulin signaling in the hypothalamus targeting energy homeostasis. Front Endocrinol (Lausanne) 2016;7:138-44.
69. Martinez-Sanchez N, Seoane-Collazo P, Contreras C, Varela L, Villarroya J, Rial-Pensado E, et al. Hypothalamic AMPK-ER stresseJNK1 axis mediates the central actions of thyroid hormones on energy balance. Cell Metabol 2017;26:212-29.
70. Xiao Y, Deng Y, Yuan F, Xia T, Liu H, Li Z, et al. ATF4/ATG5 signaling in hypothalamic proopiomelanocortin neurons regulates fat mass via affecting energy expenditure. Diabetes 2017;66:1146-58.
71. Wang GL, Fu YC, Xu WC, Feng YQ, Fang SR, Zhou XH. Resveratrol inhibits the expression of SREBP1 in cell model of steatosis via Sirt1-FOXO1 signaling pathway. Biochem Biophys Res Commun 2009;380:644-9.
72. Andrade JM, Paraiso AF, de Oliveira MV, Martins AM, Neto JF, Guimaraes AL, et al. Resveratrol attenuates hepatic steatosis in highfat fed mice by decreasing lipogenesis and inflammation. Nutrition 2014;30:915-9.
73. Tian Y, Ma J, Wang W, Zhang L, Xu J, Wang K, et al. Resveratrol supplement inhibited the NF-kappaB inflammation pathway through activating AMPKalpha-SIRT1 pathway in mice with fatty liver. Mol Cell Biochem 2016;422:75-84.
74. Shang J, Chen LL, Xiao FX, Sun H, Ding HC, Xiao H. Resveratrol improves non-alcoholic fatty liver disease by activating AMPactivated protein kinase. Acta Pharmacol Sin 2008;29:698-706.
75. Zhang Y, Chen ML, Zhou Y, Yi L, Gao YX, Ran L, et al. Resveratrol improves hepatic steatosis by inducing autophagy through the cAMP signaling pathway. Mol Nutr Food Res 2015;59:1443-57.
76. Alberdi G, Rodriguez VM, Macarulla MT, Miranda J, Churruca I, Portillo MP. Hepatic lipid metabolic pathways modified by resveratrol in rats fed an obesogenic diet. Nutrition 2013;29:562-7.
77. Wang S, Liang X, Yang Q, Fu X, Rogers CJ, Zhu M, et al. Resveratrol induces brown-like adipocyte formation in white fat through activation of AMP-activated protein kinase (AMPK) alpha 1. Int J Obes 2015;39:967-76.
78. Yang SJ, Lim Y. Resveratrol ameliorates hepatic metaflammation and inhibits NLRP3 inflammasome activation. Metabolism 2014;63: 693-701.
79. Li L, Hai J, Li Z, Zhang Y, Peng H, Li K, et al. Resveratrol modulates autophagy and NF-kappaB activity in a murine model for treating non-alcoholic fatty liver disease. Food Chem Toxicol 2014;63: 166-73.
80. Ji G, Wang Y, Deng Y, Li X, Jiang Z. Resveratrol ameliorates hepatic steatosis and inflammation in methionine/choline-deficient dietinduced steatohepatitis through regulating autophagy. Lipids Health Dis 2015;14:134-42.
81. Jin SH, Yang JH, Shin BY, Seo K, Shin SM, Cho IJ, et al. Resveratrol inhibits LXR alpha-dependent hepatic lipogenesis through novel antioxidant sestrin2 gene induction. Toxicol Appl Pharmacol 2013; 271:95-105.
82. Chen CY, Jang JH, Li MH, Surh YJ. Resveratrol upregulates heme oxygenase-1 expression via activation of NF-E2-related factor 2 in PC12 cells. Biochem Biophys Res Commun 2005;331:993-1000.
83. Ungvari Z, Bagi Z, Feher A, Recchia FA, Sonntag WE, Pearson K, et al. Resveratrol confers endothelial protection via activation of the antioxidant transcription factor Nrf2. Am J Physiol Heart Circ Physiol 2010;299:H18-24.
84. Cote CD, Rasmussen BA, Duca FA, Zadeh-Tahmasebi M, Baur JA, Daljeet M, et al. Resveratrol activates duodenal Sirt1 to reverse insulin resistance in rats through a neuronal network. Nat Med 2015; 21. 498-U284.
85. Chaplin A, Carpene C, Mercader J. Resveratrol, metabolic syndrome, and gut microbiota. Nutrients 2018;10:1651-79.
86. Bird JK, Raederstorff D, Weber P, Steinert RE. Cardiovascular and antiobesity effects of resveratrol mediated through the gut microbiota. Adv Nutr 2017;8:839-49.
87. Qiao Y, Sun J, Xia S, Tang X, Shi Y, Le G. Effects of resveratrol on gut microbiota and fat storage in a mouse model with high-fatinduced obesity. Food Funct 2014;5:1241-9.
88. Bode LM, Bunzel D, Huch M, Cho GS, Ruhland D, Bunzel M, et al. In vivo and in vitro metabolism of trans-resveratrol by human gut microbiota. Am J Clin Nutr 2013;97:295-309.
89. Leclercq IA, Farrell GC, Sempoux C, dela Pena A, Horsmans Y. Curcumin inhibits NF-kappaB activation and reduces the severity of experimental steatohepatitis in mice. J Hepatol 2004;41:926-34.
90. Ramirez-Tortosa MC, Ramirez-Tortosa CL, Mesa MD, Granados S, Gil A, Quiles JL. Curcumin ameliorates rabbits’s steatohepatitis via respiratory chain, oxidative stress, and TNF-alpha. Free Radic Biol Med 2009;47:924-31.
91. Li JM, Li YC, Kong LD, Hu QH. Curcumin inhibits hepatic proteintyrosine phosphatase 1B and prevents hypertriglyceridemia and hepatic steatosis in fructose-fed rats. Hepatology 2010;51:1555-66.
92. Wang L, Lv Y, Yao H, Yin L, Shang J. Curcumin prevents the nonalcoholic fatty hepatitis via mitochondria protection and apoptosis reduction. Int J Clin Exp Pathol 2015;8:11503-9.
93. Vizzutti F, Provenzano A, Galastri S, Milani S, Delogu W, Novo E, et al. Curcumin limits the fibrogenic evolution of experimental steatohepatitis. Lab Investig 2010;90:104-15.
94. Lin J, Tang Y, Kang Q, Feng Y, Chen A. Curcumin inhibits gene expression of receptor for advanced glycation end-products (RAGE) in hepatic stellate cells in vitro by elevating PPARgamma activity and attenuating oxidative stress. Br J Pharmacol 2012;166:2212-27.
95. Tang Y, Chen A. Curcumin eliminates the effect of advanced glycation end-products (AGEs) on the divergent regulation of gene expression of receptors of AGEs by interrupting leptin signaling. Lab Investig 2014;94:503-16.
96. Lin J, Zheng S, Chen A. Curcumin attenuates the effects of insulin on stimulating hepatic stellate cell activation by interrupting insulin signaling and attenuating oxidative stress. Lab Investig 2009;89: 1397-409.
97. Yan C, Zhang Y, Zhang X, Aa J, Wang G, Xie Y. Curcumin regulates endogenous and exogenous metabolism via Nrf2-FXR-LXR pathway in NAFLD mice. Biomed Pharmacother 2018;105:274-81.
98. Kang OH, Kim SB, Seo YS, Joung DK, Mun SH, Choi JG, et al. Curcumin decreases oleic acid-induced lipid accumulation via AMPK phosphorylation in hepatocarcinoma cells. Eur Rev Med Pharmacol Sci 2013;17:2578-86.
99. Um MY, Hwang KH, Ahn J, Ha TY. Curcumin attenuates dietinduced hepatic steatosis by activating AMP-activated protein kinase. Basic Clin Pharmacol Toxicol 2013;113:152-7.
100. Yin HP, Guo Q, Li X, Tang TT, Li CL, Wang HX, et al. Curcumin suppresses IL-1 beta secretion and prevents inflammation through inhibition of the NLRP3 inflammasome. J Immunol 2018;200: 2835-46.
101. Kong F, Ye B, Cao J, Cai X, Lin L, Huang S, et al. Curcumin represses NLRP3 inflammasome activation via TLR4/MyD88/NFkappaB and P2X7R signaling in PMA-induced macrophages. Front Pharmacol 2016;7:369.
102. Feng W, Wang H, Zhang P, Gao C, Tao J, Ge Z, et al. Modulation of gut microbiota contributes to curcumin-mediated attenuation of hepatic steatosis in rats. Biochim Biophys Acta Gen Subj 2017;1861: 1801-12.
103. Shen L, Liu L, Ji HF. Regulative effects of curcumin spice administration on gut microbiota and its pharmacological implications. Food Nutr Res 2017;61:1361780.
104. Zhang Z, Zhang H, Li B, Meng X, Wang J, et al. Berberine activates thermogenesis in white and brown adipose tissue. Nat Commun 2014; 5:5493-507.
105. Zhou H, Feng L, Xu F, Sun Y, Ma Y, Zhang X, et al. Berberine inhibits palmitate-induced NLRP3 inflammasome activation by triggering autophagy in macrophages: a new mechanism linking berberine to insulin resistance improvement. Biomed Pharmacother 2017;89:864-74.
106. Vivoli E, Cappon A, Milani S, Piombanti B, Provenzano A, Novo E, et al. NLRP3 inflammasome as a target of berberine in experimental murine liver injury: interference with P2X(7) signalling. Clin Sci 2016;130:1793-806.
107. Mahmoud AM, Hozayen WG, Ramadan SM. Berberine ameliorates methotrexate-induced liver injury by activating Nrf2/HO-1 pathway and PPARgamma, and suppressing oxidative stress and apoptosis in rats. Biomed Pharmacother 2017;94:280-91.
108. Dinesh P, Rasool M. Berberine, an isoquinoline alkaloid suppresses TXNIP mediated NLRP3 inflammasome activation in MSU crystal stimulated RAW 264.7 macrophages through the upregulation of Nrf2 transcription factor and alleviates MSU crystal induced inflammation in rats. Int Immunopharmacol 2017;44:26-37.
109. Sun Y, Yuan X, Zhang F, Han Y, Chang X, Xu X, et al. Berberine ameliorates fatty acid-induced oxidative stress in human hepatoma cells. Sci Rep 2017;7:11340.
110. Lee YS, Kim WS, Kim KH, Yoon MJ, Cho HJ, Shen Y, et al. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulinresistant states. Diabetes 2006;55:2256-64.
111. Kim WS, Lee YS, Cha SH, Jeong HW, Choe SS, Lee MR, et al. Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity. Am J Physiol Endocrinol Metab 2009;296:E812-9.
112. Sun R, Yang N, Kong B, Cao B, Feng D, Yu X, et al. Orally administered berberine modulates hepatic lipid metabolism by altering microbial bile acid metabolism and the intestinal FXR signaling pathway. Mol Pharmacol 2017;91:110-22.
113. Zhang X, Zhao Y, Xu J, Xue Z, Zhang M, Pang X, et al. Modulation of gut microbiota by berberine and metformin during the treatment of high-fat diet-induced obesity in rats. Sci Rep 2015;5:14405.
114. Zhang X, Zhao Y, Zhang M, Pang X, Xu J, Kang C, et al. Structural changes of gut microbiota during berberine-mediated prevention of obesity and insulin resistance in high-fat diet-fed rats. PLoS One 2012;7. e42529.
115. Feng R, Shou JW, Zhao ZX, He CY, Ma C, Huang M, et al. Transforming berberine into its intestine-absorbable form by the gut microbiota. Sci Rep 2015;5:12155.
116. Wang Y, Tong Q, Shou JW, Zhao ZX, Li XY, Zhang XF, et al. Gut microbiota-mediated personalized treatment of hyperlipidemia using berberine. Theranostics 2017;7:2443-51.
117. Wang Y, Shou JW, Li XY, Zhao ZX, Fu J, He CY, et al. Berberineinduced bioactive metabolites of the gut microbiota improve energy metabolism. Metabolism 2017;70:72-84.
118. Salomone F, Barbagallo I, Godos J, Lembo V, Currenti W, Cina D, et al. Silibinin restores NAD+ levels and induces the SIRT1/AMPK pathway in non-alcoholic fatty liver. Nutrients 2017;9.
119. Gu M, Zhao P, Huang J, Zhao Y, Wang Y, Li Y, et al. Silymarin ameliorates metabolic dysfunction associated with diet-induced obesity via activation of farnesyl X receptor. Front Pharmacol 2016;7:345.
120. Cui CX, Deng JN, Yan L, Liu YY, Fan JY, Mu HN, et al. Silibinin capsules improves high fat diet-induced nonalcoholic fatty liver disease in hamsters through modifying hepatic de novo lipogenesis and fatty acid oxidation. J Ethnopharmacol 2017;208:24-35.
121. Zhang BL, Xu D, She LL, Wang ZX, Yang N, Sun RB, et al. Silybin inhibits NLRP3 inflammasome assembly through the NAD+/SIRT2 pathway in mice with nonalcoholic fatty liver disease. FASEB J 2018; 32:757-67.
122. Surai PF. Silymarin as a natural antioxidant: an overview of the current evidence and perspectives. Antioxidants 2015;4:204-47.
123. Charytoniuk T, Drygalski K, Konstantynowicz-Nowicka K, Berk K, Chabowski A. Alternative treatment methods attenuate the development of NAFLD: a review of resveratrol molecular mechanisms and clinical trials. Nutrition 2017;34:108-17.
124. Poulsen MM, Vestergaard PF, Clasen BF, Radko Y, Christensen LP, Stodkilde-Jorgensen H, et al. High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebocontrolled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes 2013;62:1186-95.
125. Yoshino J, Conte C, Fontana L, Mittendorfer B, Imai S, Schechtman KB, et al. Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance. Cell Metabol 2012;16:658-64.
126. Elgebaly A, Radwan IA, AboElnas MM, Ibrahim HH, Eltoomy MF, Atta AA, et al. Resveratrol supplementation in patients with nonalcoholic fatty liver disease: systematic review and meta-analysis. J Gastrointest Liver Dis 2017;26:59-67.
127. Liang L, Liu X, Wang Q, Cheng S, Zhang S, Zhang M. Pharmacokinetics, tissue distribution and excretion study of resveratrol and its prodrug 3,5,4'-tri-O-acetylresveratrol in rats. Phytomedicine 2013; 20:558-63.
128. Farzaei MH, Zobeiri M, Parvizi F, El-Senduny FF, Marmouzi I, CoyBarrera E, et al. Curcumin in liver diseases: a systematic review of the cellular mechanisms of oxidative stress and clinical perspective. Nutrients 2018;10:855-82.
129. White CM, Lee JY. The impact of turmeric or its curcumin extract on nonalcoholic fatty liver disease: a systematic review of clinical trials. Pharm Pract (Granada) 2019;17:1350.
130. Rahmani S, Asgary S, Askari G, Keshvari M, Hatamipour M, Feizi A, et al. Treatment of non-alcoholic fatty liver disease with curcumin: a randomized placebo-controlled trial. Phytother Res 2016;30:1540-8.
131. Afrin R, Arumugam S, Rahman A, Wahed MI, Karuppagounder V, Harima M, et al. Curcumin ameliorates liver damage and progression of NASH in NASH-HCC mouse model possibly by modulating HMGB1-NF-kappaB translocation. Int Immunopharmacol 2017;44: 174-82.
132. Gong Z, Zhou J, Li H, Gao Y, Xu C, Zhao S, et al. Curcumin suppresses NLRP3 inflammasome activation and protects against LPS-induced septic shock. Mol Nutr Food Res 2015;59: 2132-42.
133. Kong WJ, Wei J, Abidi P, Lin MH, Inaba S, Li C, et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med 2004;10:1344-51.
134. Liu Y, Zhang L, Song H, Ji G. Update on berberine in nonalcoholic fatty liver disease. Evid Based Complement Altern Med 2013;2013: 308134.
135. Chang X, Wang Z, Zhang J, Yan H, Bian H, Xia M, et al. Lipid profiling of the therapeutic effects of berberine in patients with nonalcoholic fatty liver disease. J Transl Med 2016;14:266-76.
136. Wei X, Wang C, Hao S, Song H, Yang L. The therapeutic effect of berberine in the treatment of nonalcoholic fatty liver disease: a meta-analysis. Evid Based Complement Altern Med 2016;2016: 3593951.
137. Yang J, Ma XJ, Li L, Wang L, Chen YG, Liu J, et al. Berberine ameliorates non-alcoholic steatohepatitis in ApoEe/e mice. Exp Ther Med 2017;14:4134-40.
138. Guo T, Woo SL, Guo X, Li H, Zheng J, Botchlett R, et al. Berberine ameliorates hepatic steatosis and suppresses liver and adipose tissue inflammation in mice with diet-induced obesity. Sci Rep 2016;6: 22612.
139. Cacciapuoti F, Scognamiglio A, Palumbo R, Forte R, Cacciapuoti F. Silymarin in non alcoholic fatty liver disease. World J Hepatol 2013; 5:109-13.
140. Ou Q, Weng Y, Wang S, Zhao Y, Zhang F, Zhou J, et al. Silybin alleviates hepatic steatosis and fibrosis in NASH mice by inhibiting oxidative stress and involvement with the NF-kB pathway. Dig Dis Sci 2018;63:3398-408.
141. Salamone F, Galvano F, Cappello F, Mangiameli A, Barbagallo I, Li Volti G. Silibinin modulates lipid homeostasis and inhibits nuclear factor kappa B activation in experimental nonalcoholic steatohepatitis. Transl Res 2012;159:477-86.
142. Ni XJ, Wang HY. Silymarin attenuated hepatic steatosis through regulation of lipid metabolism and oxidative stress in a mouse model of nonalcoholic fatty liver disease (NAFLD). Am J Transl Res 2016; 8:1073-81.
143. Marin V, Gazzin S, Gambaro SE, Dal Ben M, Calligaris S, Anese M, et al. Effects of oral administration of silymarin in a juvenile murine model of non-alcoholic steatohepatitis. Nutrients 2017;9:1006-25.
144. Solhi H, Ghahremani R, Kazemifar AM, Hoseini Yazdi Z. Silymarin in treatment of non-alcoholic steatohepatitis: a randomized clinical trial. Caspian J Intern Med 2014;5:9-12.
145. Aller R, Izaola O, Gomez S, Tafur C, Gonzalez G, Berroa E, et al. Effect of silymarin plus vitamin E in patients with non-alcoholic fatty liver disease: a randomized clinical pilot study. Eur Rev Med Pharmacol Sci 2015;19:3118-24.
146. de Avelar CR, Pereira EM, de Farias Costa PR, de Jesus RP, de Oliveira LPM. Effect of silymarin on biochemical indicators in patients with liver disease: systematic review with meta-analysis. World J Gastroenterol 2017;23:5004-17.
147. Federico A, Trappoliere M, Tuccillo C, de Sio I, Di Leva A, Del Vecchio Blanco C, et al. A new silybin-vitamin E-phospholipid complex improves insulin resistance and liver damage in patients with non-alcoholic fatty liver disease: preliminary observations. Gut 2006;55:901-2.
148. Andreone P, Brisc MC, Chiaramonte M, Federico A, Floreani A, Freni MA, et al. Silybin conjugated with phosphatidylcholine and vitamin E improves liver damage in patients with NAFLD: the results of a randomized multicentre double-blind vs. placebo trial. J Hepatol 2011;54:S330-1.
149. Kim M, Yang SG, Kim JM, Lee JW, Kim YS, Lee JI. Silymarin suppresses hepatic stellate cell activation in a dietary rat model of non-alcoholic steatohepatitis: analysis of isolated hepatic stellate cells. Int J Mol Med 2012;30:473-9.
150. Shen L, Ji HF. Intestinal microbiota and metabolic diseases: pharmacological implications. Trends Pharmacol Sci 2016;37:169-71.
151. Abenavoli L, Izzo AA, Milic N, Cicala C, Santini A, Capasso R. Milk thistle (Silybum marianum): a concise overview on its chemistry, pharmacological, and nutraceutical uses in liver diseases. Phytother Res 2018;32:2202-13.
152. Serviddio G, Bellanti F, Giudetti AM, Gnoni GV, Petrella A, Tamborra R, et al. A silybin-phospholipid complex prevents mitochondrial dysfunction in a rodent model of nonalcoholic steatohepatitis. J Pharmacol Exp Ther 2010;332:922-32.
153. Patel DP, Yan T, Kim D, Dias HB, Krausz KW, Kimura S, et al. Withaferin A improves non-alcoholic steatohepatitis in mice. J Pharmacol Exp Ther 2019;371:360-74.
154. Yan T, Wang H, Cao L, Wang Q, Takahashi S, Yagai T, et al. Glycyrrhizin alleviates nonalcoholic steatohepatitis via modulating bile acids and meta-inflammation. Drug Metab Dispos 2018;46: 1310-9.
155. Sun X, Duan X, Wang C, Liu Z, Sun P, Huo X, et al. Protective effects of glycyrrhizic acid against non-alcoholic fatty liver disease in mice. Eur J Pharmacol 2017;806:75-82.
156. Wu X, Zhang L, Gurley E, Studer E, Shang J, Wang T, et al. Prevention of free fatty acid-induced hepatic lipotoxicity by 18betaglycyrrhetinic acid through lysosomal and mitochondrial pathways. Hepatology 2008;47:1905-15.
157. Xin HG, Zhang BB, Wu ZQ, Hang XF, Xu WS, Ni W, et al. Treatment with baicalein attenuates methionine-choline deficient diet-induced non-alcoholic steatohepatitis in rats. Eur J Pharmacol 2014;738:310-8.
158. Zhang J, Zhang H, Deng X, Zhang Y, Xu K. Baicalin protects AML-12 cells from lipotoxicity via the suppression of ER stress and TXNIP/NLRP3 inflammasome activation. Chem Biol Interact 2017; 278:189-96.
159. Shetty SN, Mengi S, Vaidya R, Vaidya AD. A study of standardized extracts of Picrorhiza kurroa Royle ex Benth in experimental nonalcoholic fatty liver disease. J Ayurveda Integr Med 2010;1: 203-10.
160. Yang QH, Xu YJ, Liu YZ, Liang YJ, Feng GF, Zhang YP, et al. Effects of chaihu-shugan-san and shen-ling-bai-zhu-san on p38 MAPK pathway in kupffer cells of nonalcoholic steatohepatitis. Evid Based Complement Altern Med 2014;2014:671013.
161. Yang Q, Xu Y, Feng G, Hu C, Zhang Y, Cheng S, et al. p38 MAPK signal pathway involved in anti-inflammatory effect of ChaihuShugan-San and Shen-ling-bai-zhu-San on hepatocyte in nonalcoholic steatohepatitis rats. Afr J Tradit, Complementary Altern Med 2014;11:213-21.
162. Takahashi Y, Soejima Y, Kumagai A, Watanabe M, Uozaki H, Fukusato T. Japanese herbal medicines shosaikoto, inchinkoto, and juzentaihoto inhibit high-fat diet-induced nonalcoholic steatohepatitis in db/db mice. Pathol Int 2014;64:490-8.
163. Takahashi Y, Soejima Y, Kumagai A, Watanabe M, Uozaki H, Fukusato T. Inhibitory effects of Japanese herbal medicines shosaiko-to and juzen-taiho-to on nonalcoholic steatohepatitis in mice. PLoS One 2014;9. e87279.
164. Li XX, Lu XY, Zhang SJ, Chiu AP, Lo LH, Largaespada DA, et al. Sodium tanshinone IIA sulfonate ameliorates hepatic steatosis by inhibiting lipogenesis and inflammation. Biomed Pharmacother 2019;111:68-75.
165. Ono M, Ogasawara M, Hirose A, Mogami S, Ootake N, Aritake K, et al. Bofutsushosan, a Japanese herbal (Kampo) medicine, attenuates progression of nonalcoholic steatohepatitis in mice. J Gastroenterol 2014;49:1065-73.
166. Yu N, Fang X, Zhao D, Mu Q, Zuo J, Ma Y, et al. Anti-diabetic effects of jiang tang xiao ke granule via PI3K/Akt signalling pathway in type 2 diabetes kkay mice. PLoS One 2017;12. e0168980.
167. Mo FF, An T, Zhang ZJ, Liu YF, Liu HX, Pan YY, et al. Jiang tang xiao ke granule play an anti-diabetic role in diabetic mice pancreatic tissue by regulating the mRNAs and microRNAs associated with PI3K-Akt signaling pathway. Front Pharmacol 2017;8: 795.
168. Zhang Y, An H, Pan SY, Zhao DD, Zuo JC, Li XK, et al. Jiang tang xiao ke granule, a classic Chinese herbal formula, improves the effect of metformin on lipid and glucose metabolism in diabetic mice. Evid Based Complement Altern Med 2016;2016. 1592731.
169. Liang Y, Zhang Y, Deng Y, Liang S, He Y, Chen Y, et al. Chaihushugan-san decoction modulates intestinal microbe dysbiosis and alleviates chronic metabolic inflammation in NAFLD rats via the NLRP3 inflammasome pathway. Evid Based Complement Altern Med 2018;2018:9390786.
170. Jiang WN, Li D, Jiang T, Guo J, Chen YF, Wang J, et al. Protective effects of chaihu shugan san on nonalcoholic fatty liver disease in rats with insulin resistance. Chin J Integr Med 2018;24:125-32.
171. Guo H, Zhong R, Liu Y, Jiang X, Tang X, Li Z, et al. Effects of bayberry juice on inflammatory and apoptotic markers in young adults with features of non-alcoholic fatty liver disease. Nutrition 2014;30:198-203.
172. Xiao J, Wang F, Liong EC, So KF, Tipoe GL. Lycium barbarum polysaccharides improve hepatic injury through NF-kB and NLRP3/6 pathways in a methionine choline deficient diet steatohepatitis mouse model. Int J Biol Macromol 2018;120:1480-9.
173. Li G, Zhou F, Chen Y, Zhang W, Wang N. Kukoamine A attenuates insulin resistance and fatty liver through downregulation of SREBP-1c. Biomed Pharmacother 2017;89:536-43.
174. Jia L, Li W, Li J, Li Y, Song H, Luan Y, et al. Lycium barbarum polysaccharide attenuates high-fat diet-induced hepatic steatosis by up-regulating SIRT1 expression and deacetylase activity. Sci Rep 2016;6:36209.
175. Xiao J, Xing F, Huo J, Fung ML, Liong EC, Ching YP, et al. Lycium barbarum polysaccharides therapeutically improve hepatic functions in non-alcoholic steatohepatitis rats and cellular steatosis model. Sci Rep 2014;4:5587.
176. Zamani N, Shams M, Nimrouzi M, Zarshenas MM, Abolhasani Foroughi A, Fallahzadeh Abarghooei E, et al. The effects of Zataria multiflora Boiss. (Shirazi thyme) on nonalcoholic fatty liver disease and insulin resistance: a randomized double-blind placebo-controlled clinical trial. Complement Ther Med 2018;41:118-23.
177. Li J, Wang S, Yao L, Ma P, Chen Z, Han TL, et al. 6-Gingerol ameliorates age-related hepatic steatosis association with regulating lipogenesis, fatty acid oxidation, oxidative stress and mitochondrial dysfunction. Toxicol Appl Pharmacol 2019;362:125-35.
178. Lai YS, Lee WC, Lin YE, Ho CT, Lu KH, Lin SH, et al. Ginger essential oil ameliorates hepatic injury and lipid accumulation in high fat diet-induced nonalcoholic fatty liver disease. J Agric Food Chem 2016;64:2062-71.
179. Hong SH, Suk KT, Choi SH, Lee JW, Sung HT, Kim CH, et al. Antioxidant and natural killer cell activity of Korean red ginseng (Panax ginseng) and urushiol (Rhus vernicifera Stokes) on nonalcoholic fatty liver disease of rat. Food Chem Toxicol 2013;55: 586-91.
180. Lee SB, Cho HI, Jin YW, Lee EK, Ahn JY, Lee SM. Wild ginseng cambial meristematic cells ameliorate hepatic steatosis and mitochondrial dysfunction in high-fat diet-fed mice. J Pharm Pharmacol 2016;68:119-27.
181. Hong M, Lee YH, Kim S, Suk KT, Bang CS, Yoon JH, et al. Antiinflammatory and antifatigue effect of Korean Red Ginseng in patients with nonalcoholic fatty liver disease. J Ginseng Res 2016;40: 203-10.
182. Jeong H, Kim JW, Yang MS, Park C, Kim JH, Lim CW, et al. Beneficial effects of Korean red ginseng in the progression of nonalcoholic steatohepatitis via FABP4 modulation. Am J Chin Med 2018;46:1581-607.
183. Huang Q, Wang T, Yang L, Wang HY. Ginsenoside Rb2 alleviates hepatic lipid accumulation by restoring autophagy via induction of Sirt1 and activation of AMPK. Int J Mol Sci 2017;18: 1063-77.
184. Xu Y, Yang C, Zhang S, Li J, Xiao Q, Huang W. Ginsenoside Rg1 protects against non-alcoholic fatty liver disease by ameliorating lipid peroxidation, endoplasmic reticulum stress, and inflammasome activation. Biol Pharm Bull 2018;41:1638-44.
185. Peng H, He Y, Zheng G, Zhang W, Yao Z, Xie W. Meta-analysis of traditional herbal medicine in the treatment of nonalcoholic fatty liver disease. Cell Mol Biol (Noisy-Le-Grand) 2016;62:88-95.
186. Sanyal AJ, Neuschwander-Tetri BA, Tonascia J. End points must be clinically meaningful for drug development in nonalcoholic fatty liver disease. Gastroenterology 2016;150:11-3.
187. Hao HP, Zheng X, Wang GJ. Insights into drug discovery from natural medicines using reverse pharmacokinetics. Trends Pharmacol Sci 2014;35:168-77.
188. Saeidnia S, Gohari AR, Manayi A. Reverse pharmacognosy and reverse pharmacology; two closely related approaches for drug discovery development. Curr Pharmaceut Biotechnol 2016;17:1016-22.
189. Hebbard L, George J. Animal models of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2011;8:35-44.
190. Stankovic MN, Mladenovic DR, Duricic I, Sobajic SS, Timic J, Jorgacevic B, et al. Time-dependent changes and association between liver free fatty acids, serum lipid profile and histological features in mice model of nonalcoholic fatty liver disease. Arch Med Res 2014;45: 116-24.
191. Xiong X, Kuang H, Ansari S, Liu T, Gong J, Wang S, et al. Landscape of intercellular crosstalk in healthy and NASH liver revealed by single-cell secretome gene analysis. Mol Cell 2019;75:644-60.
192. Alonso C, Fernandez-Ramos D, Varela-Rey M, Martinez-Arranz I, Navasa N, van Liempd SM, et al. Metabolomic identification of subtypes of nonalcoholic steatohepatitis. Gastroenterology 2017;152:1449-61.
193. Hussein NS, Helmy AS, Sherif NM, Ghanem HZ, Ibrahim NA, El Gendy ANG, et al. Lipidomic analysis reveals the efficiency of eclipta prostrata on diet-induced nonalcoholic fatty liver disease in rats. J Pharm Biomed Anal 2019;165:224-32.
194. Sanyal AJ, Brunt EM, Kleiner DE, Kowdley KV, Chalasani N, Lavine JE, et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 2011;54:344-53.
195. Xu J, Chen HB, Li SL. Understanding the molecular mechanisms of the interplay between herbal medicines and gut microbiota. Med Res Rev 2017;37:1140-85.
196. Wang Y, Fan X, Qu H, Gao X, Cheng Y. Strategies and techniques for multi-component drug design from medicinal herbs and traditional Chinese medicine. Curr Top Med Chem 2012;12:1356-62.
197. Chen M, Yang F, Yang X, Lai X, Gao Y. Systematic understanding of mechanisms of a Chinese herbal formula in treatment of metabolic syndrome by an integrated pharmacology approach. Int J Mol Sci 2016;17:2114-27.